GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Net Issuance of Debt

AVBP (ArriVent BioPharma) Net Issuance of Debt : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. ArriVent BioPharma's net issuance of debt for the three months ended in Mar. 2025 was $0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

ArriVent BioPharma Net Issuance of Debt Historical Data

The historical data trend for ArriVent BioPharma's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Net Issuance of Debt Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Net Issuance of Debt
- - - -

ArriVent BioPharma Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ArriVent BioPharma Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ArriVent BioPharma Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Net Issuance of Debt
Comparable Companies
GHRS RCKT IMNM NRIX REPL AVXL TRVI DAWN GYRE PRAX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073
Website
https://www.arrivent.com
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.